Abstract:Adipogenesis is tightly regulated by various factors, including genes and microRNAs. Excessive fat deposition is the key feature of obesity, which is a low-grade chronic inflammatory disease. Follistatin-like 1 (FSTL1) has been reported to be an important mediator involved in various inflammatory diseases. However, the underlying mechanism of FSTL1 in preadipocyte differentiation and inflammatory response is still unclear. The current study was designed to explore the biological function and potential mechanism of FSTL1 in mouse subcutaneous preadipocyte differentiation. We found that FSTL1 was highly expressed in the early stage of differentiation and subsequently decreased sharply, suggesting that FSTL1 played a possible role in adipogenesis. Meanwhile, the gain-and loss-of- function assays showed that FSTL1 was not only involved in the inflammatory response by inducing the expression of pro-inflammatory factors IL-1 beta and CCL2 but also significantly attenuated preadipocyte differentiation, as evidenced by the reduction of lipid accumulation and the levels of adipogenic genes, including PPAR. and FABP4. In addition, the target gene prediction and luciferase reporter assay validated that miR-125a- 3p targeted the 3' UTR region of FSTL1. These results demonstrated that miR-125a- 3p negatively regulated the expression of FSTL1 at the mRNA and protein levels. Furthermore, overexpressing miR-125a3p in preadipocytes dramatically accelerated adipogenic differentiation and downregulated the levels of IL-1 beta and CCL2, which were in accordance with the knockdown of FSTL1. On the contrary, treatment with miR-125a- 3p inhibitors attenuated adipogenesis but induced the expression of inflammatory genes. In summary, this study suggests a positive function of FSTL1 in adipocyte-induced inflammation and negatively regulates preadipocyte differentiation. Further studies demonstrated that miR-125a- 3p could reverse the effect by targeting FSTL1, which might provide a better understanding of treating obesity-related inflammatory diseases.

Sclerostin Enhances Adipocyte Differentiation in 3T3‐L1 Cells

SOST Gene Inhibits Osteogenesis from Adipose-Derived Mesenchymal Stem Cells by Inducing Th17 Cell Differentiation

Zinc Finger Protein 467 Regulates Wnt Signaling by Modulating the Expression of Sclerostin in Adipose Derived Stem Cells

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

miR-125a-3p regulates the expression of FSTL1, a pro-inflammatory factor, during adipogenic differentiation, and inhibits adipogenesis in mice

Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR-mediated inhibition of autophagy under hyperlipidemic conditions

Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Sclerostin and skeletal health

Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones

Adipocytes Enhance Expression of Osteoclast Adhesion-Related Molecules Through the Cxcl12/Cxcr4 Signalling Pathway

STAT3 Is the Master Regulator for the Forming of 3D Spheroids of 3T3-L1 Preadipocytes

Stomatin modulates adipocyte differentiation through ERK pathway and regulates lipid droplet growth and function

The Role of Sclerostin in Lipid and Glucose Metabolism Disorders

The Effect of Myostatin on Proliferation and Lipid Accumulation in 3T3-L1 Preadipocytes

Signal transducer and activator of transcription 3 (STAT3) regulates adipocyte differentiation via peroxisome-proliferator-activated receptor γ (PPARγ)

Sclerostin modulates mineralization degree and stiffness profile in the fibrocartilaginous enthesis for mechanical tissue integrity

Sirtuin1 Promotes Osteogenic Differentiation Through Downregulation of Peroxisome Proliferator-Activated Receptor Γ in MC3T3-E1 Cells

Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein

Association of serum sclerostin levels with marrow adiposity in postmenopausal women with glucocorticoid-induced osteoporosis

Dose-Dependent Effect of Estrogen Suppresses the Osteo-Adipogenic Transdifferentiation of Osteoblasts Via Canonical Wnt Signaling Pathway